Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

被引：2
|
作者：
Chng, W. J. [1 ]
Jacobus, S. [2 ]
Fonseca, R. [1 ]
机构：
[1] Mayo Clin, Comprehens Canc Ctr, Scottsdale, AZ USA
[2] Dana Faber Canc Inst, Eastern Coop Oncol Grp Stat Ctr, Boston, MA USA
来源：
LEUKEMIA | 2008年 / 22卷 / 05期
关键词：
D O I：
10.1038/sj.leu.2405009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1080 / 1081
页数：3
相关论文
共 41 条
  • [31] Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study
    Chalopin, Thomas
    Vallet, Nicolas
    Ochmann, Marlene
    Tiab, Mourad
    Godmer, Pascal
    Barin, Carole
    Theisen, Olivier
    Herault, Olivier
    Gyan, Emmanuel
    Benboubker, Lotfi
    Moreau, Philippe
    Avet-Loiseau, Herve
    Touzeau, Cyrille
    BLOOD, 2020, 136
  • [32] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group (vol 58, pg 1, 2017)
    Grzasko, R.
    Hajek, R.
    Hus, M.
    LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2518 - 2518
  • [33] Over 30% of newly diagnosed multiple myeloma with the t(4;14) (p16;q32) translocation lack FGFR3 expression, yet have the IGH/MMSET fusion transcript.
    Santra, M
    Zhan, FH
    Tian, EM
    Yan, X
    Barlogie, B
    Shaughnessy, J
    BLOOD, 2002, 100 (11) : 101A - 101A
  • [34] High-Risk Genetic Prognostic Factors Including 17p(p53) Deletion, 1q21 Gains and 1p21 Loss Do Not Affect Bortezomib Therapy Responsiveness and Survival of Relapsed/Refractory Myeloma Patients
    Qi, C.
    Trieu, Y.
    Reece, D.
    Chang, H.
    MODERN PATHOLOGY, 2009, 22 : 281A - 281A
  • [35] High-Risk Genetic Prognostic Factors Including 17p(p53) Deletion, 1q21 Gains and 1p21 Loss Do Not Affect Bortezomib Therapy Responsiveness and Survival of Relapsed/Refractory Myeloma Patients
    Qi, C.
    Trieu, Y.
    Reece, D.
    Chang, H.
    LABORATORY INVESTIGATION, 2009, 89 : 281A - 281A
  • [36] Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)
    Richardson, Paul G.
    Jakubowiak, Andrzej
    Bahlis, Nizar J.
    Siegel, David S.
    Chen, Christine I.
    Chen, Min
    Zaki, Mohamed
    Larkins, Gail
    Anderson, Kenneth C.
    BLOOD, 2012, 120 (21)
  • [37] AN ASSAY FOR SIMULTANEOUS DIAGNOSIS OF T(4;14), T(11;14), T(14;16)/T(14;20), DEL1P, ADD1Q, DEL13Q, DEL17P, MS/MF EXPRESSION CLUSTERS, AND THE SKY-92 HIGH RISK SIGNATURE IN MULTIPLE MYELOMA PATIENTS
    Van Vliet, M.
    Kuiper, R.
    Broijl, A.
    de Knegt, Y.
    Hoos, W.
    de Best, L.
    van Duin, M.
    Van Beers, E.
    Sonneveld, P.
    HAEMATOLOGICA, 2013, 98 : 101 - 101
  • [38] Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial
    Neben, Kai
    Lokhorst, Henk M.
    Jauch, Anna
    Bertsch, Uta
    Hielscher, Thomas
    Heiss, Christiane
    van der Holt, Bronno
    Schmitt, Stefan
    El Jarari, Laila
    Salwender, Hans J.
    Blau, Igor W.
    Pfreundschuh, Michael
    Weisel, Katja
    Duehrsen, Ulrich
    Lindemann, Walter
    Teschendorf, Christian
    Martin, Hans
    Scheid, Christof
    Haenel, Mathias
    Derigs, Hans Guenter
    Graeven, Ullrich
    Schmidt-Wolf, Ingo G. H.
    Peter, Norma
    Wattad, Mohammed
    Luntz, Steffen P.
    Broyl, Annemiek
    Schubert, Joerg
    Hoffmann, Martin
    Goerner, Martin
    Tischler, Jochen
    Kaufmann, Martin
    Raab, Marc S.
    Ho, Anthony D.
    van de Velde, Helgi
    Hose, Dirk
    Sonneveld, Pieter
    Goldschmidt, Hartmut
    BLOOD, 2011, 118 (21) : 156 - 156
  • [39] No adverse impact of 13q14 and P53 deletion, t(4;14)(p16;q32) or overrepresentation of CMYC(8q24) as detected by fluorescence in situ hybridization on outcome in patients with multiple myeloma following dose-reduced allogeneic stem cell transplantation.
    Hansen, Timon
    Schilling, Georgia
    Liebisch, Peter
    Schwerdtfeger, Rainer
    Perez-Simon, Jose Antonio
    Bornhaeuser, Martin
    Otterstetter, Svenja
    Dierlamm, Judith
    Nagler, Arnon
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    Zander, Axel R.
    Kroeger, Nicolaus
    BLOOD, 2006, 108 (11) : 348B - 349B
  • [40] Total therapy 2 (No thalidomide arm, TT2-) is superior to total therapy 1 (TT1) for newly diagnosed multiple myeloma (MM): Doubling 4-yr survival among patients with cytogenetic abnormalities (CA) due to consolidation chemotherapy (CCT) and DEX maintenance.
    Barlogie, B
    Tricot, G
    Rasmussen, E
    Anaissie, E
    van Rhee, F
    Zangari, M
    Hollmig, K
    Milner, T
    Epstein, J
    Shaughnessy, J
    Crowley, J
    BLOOD, 2005, 106 (11) : 336A - 336A
12345